insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

AIBT · Aibotics, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23
Revenue-$0$0$0------
Cost of Revenue----------
Gross Profit-$0$0$0------
R&D----------
SG&A-$480.4K$360.6K$531.6K-$385.3K$391.4K$360.9K-$165.4K
Total Operating Expenses-$480.4K$360.6K$531.6K-$385.3K$391.4K$360.9K-$165.4K
D&A$0$0$0$0$498$498$498$249$998$747
Operating Income-($480.4K)($360.6K)($529.5K)-($385.3K)($391.4K)($360.9K)-($165.4K)
Interest Expense-$11.2K$70.1K$61.9K-$74.9K$79.3K$65.1K-$143.3K
Income Tax-$0$0$0-$0$0$0-$0
Net Income-($529.9K)($486.1K)($591.4K)-($460.1K)($470.7K)($425.9K)-($308.7K)
EPS - Basic----------
EPS - Diluted----------

Balance Sheet

Line itemQ4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23
Cash & Equivalents$255.9K$230.5K$242.2K$156.7K$185.1K$202.4K$279.9K$370.4K$279.1K$317.0K
Accounts Receivable----------
Inventory----------
Accounts Payable----------
Current Assets$270.1K$241.4K$242.2K$156.7K$185.1K$203.1K$280.4K$370.9K$279.1K$317.0K
Total Assets$874.7K$1.02M$1.19M$1.26M$1.46M$1.64M$1.89M$2.14M$2.22M$317.7K
Current Liabilities$4.79M$4.90M$5.39M$5.10M$4.85M$5.00M$4.81M$4.60M$4.25M$2.06M
Long-term Debt----------
Total Liabilities$4.83M$4.90M$5.39M$5.10M$4.85M$5.00M$4.81M$4.60M$4.25M$2.06M
Stockholders' Equity($3.96M)($3.89M)($4.21M)($3.84M)($3.39M)($3.36M)($2.92M)($2.45M)($2.03M)($1.74M)
Retained Earnings($13.03M)($12.42M)($11.89M)($11.40M)($10.81M)($10.32M)($9.86M)($9.39M)($8.96M)($8.67M)

Cash Flow

Line itemQ4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23
Operating Cash Flow---($28.4K)---($73.7K)--
Investing Cash Flow---$0---$0--
Financing Cash Flow---$0---$165.0K--
CapEx----------
Free Cash Flow----------

Ratios

MetricQ4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets--52.1%-41.0%-46.8%--28.0%-24.9%-19.9%--97.2%
Return on equity-13.6%11.6%15.4%-13.7%16.1%17.4%-17.8%
Return on invested capital----------
Liquidity
Current ratio0.060.050.040.030.040.040.060.080.070.15
Quick ratio0.060.050.040.030.040.040.060.080.070.15
Cash ratio0.050.050.040.030.040.040.060.080.070.15
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage--43.1x-5.1x-8.5x--5.1x-4.9x-5.5x--1.2x
Equity multiplier-0.22-0.26-0.28-0.33-0.43-0.49-0.65-0.87-1.09-0.18
Liabilities / Assets5.534.824.554.033.333.042.552.141.916.47
Efficiency
Asset turnover-0.000.000.00------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)--24.7%7.9%-46.7%--132.9%-233.5%-148.9%-48.7%
Net income growth (YoY)--15.2%-3.3%-38.8%--49.1%-68.9%-40.6%-39.2%
EPS growth (YoY)----------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-16.7%-15.7%-43.9%-56.3%-67.4%-93.3%-104.7%-105.5%-127.6%-638.5%

Peer comparison

Same SIC group: Medicinal Chemicals & Botanical Products

CompanyRevenue (last FY)Net marginROE
USNA$925.26M1.2%2.0%
TRUL$1.18B-9.9%-10.2%
CRON$146.59M-6.4%-0.9%
CYAN$24.21M-13.2%-36.1%
MNMD---55.3%

Comparing AIBOTICS against the 5 most active filers in the same SIC group.